Revista nº 807

López-Zúñiga M. A . et al. Perfil lipídico interdosis de iPCSK9 Actualidad Médica · Número 807 · Mayo/Agosto 2019 Páginas 98 a 102 · 102 · 6. Ogura M. PCSK9 inhibition in the management of familial hypercholesterolemia. J Cardiol. 2018; 71(1):1-7. 7. Landmesser U, Chapman MJ, Stock JK, Amarenco P, Belch JJF, Borén J, et al. 2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertasesubtilisin/ kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia. Eur Heart J. 2018; 39(14):1131-1143. 8. Page MM, Watts GF. PCSK9 in context: A contemporary review of an important biological target for the prevention and treatment of atherosclerotic cardiovascular Disease. Diabetes Obes Metab. 2018; 20(2):270-282. 9. Di Bartolo B, Scherer DJ, Brown A, Psaltis PJ, Nicholls SJ. PCSK9 Inhibitors in Hyperlipidemia: Current Status and Clinical Outlook. BioDrugs. 2017; 31(3):167-174. 10. Filippatos TD, Kei A, Rizos CV, Elisaf MS. Effects of PCSK9 Inhibitors on Other than Low-Density Lipoprotein Cholesterol Lipid Variables. J Cardiovasc Pharmacol Ther. 2018; 23(1):3-12 11. Koren MJ, Roth EM, McKenney JM, Gipe D, Hanotin C, Ferrand AC, et al. Safety and efficacy of alirocumab 150 mg every 2 weeks, a fully human proprotein convertase subtilisin/kexin type 9 monoclonal antibody: A Phase II pooled analysis. Postgrad Med. 2015; 127(2):125-32. doi: 10.1080 /00325481.2015. 998987. Epub 2015 Jan 22. 12. Endocrinology and metabolic drugs advisory committee (EMDAC) meeting june 10, FDA Briefing Documente. United Sates Food and Drug Administration website. Disponible en: https://www.fda.gov/ AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ EndocrinologicandMetabolicDrugsAdvisoryCommittee/ ucm450071.htm